EP4147700A1 — N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides for use in the treatment of sickle cell disease
Assigned to Lqt Therapeutics Inc · Expires 2023-03-15 · 3y expired
What this patent protects
N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides of the formula I, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising a compound of the formula I or a pharmaceutically acceptable salt thereof, are described for use in the treatment o…
USPTO Abstract
N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides of the formula I, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising a compound of the formula I or a pharmaceutically acceptable salt thereof, are described for use in the treatment of a β-hemoglobinopathy, particularly for use in the treatment of sickle cell disease or β-thalassemia, more particularly for use in the treatment of sickle cell disease.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.